NEW YORK, NY / ACCESSWIRE / July 31, 2017 / Pomerantz LLP is investigating claims on behalf of investors of InVivo Therapeutics Holding Corp. (“InVivo” or the “Company”) (NASDAQ: NVIV). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
The investigation concerns whether InVivo and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here to join a class action]
On July 31, 2017, InVivo announced that the Company had halted a trial of its Neuro-Spinal Scaffold, a spinal cord injury treatment, after a third patient death. InVivo advised investors that the Company had decided to halt the trial while it discusses with the U.S. Food and Drug Administration whether to change the trial’s enrollment criteria.
On this news, InVivo’s share price has fallen as much as $0.80, or 32.65%, during intraday trading on July 31, 2017.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
SOURCE: Pomerantz LLP
ReleaseID: 470101
—
NEW YORK, NY / ACCESSWIRE / July 31, 2017 / Pomerantz LLP is investigating claims on behalf of investors of InVivo Therapeutics Holding Corp. (“InVivo” or the “Company”) (NASDAQ: NVIV). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
The investigation concerns whether InVivo and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here to join a class action]
On July 31, 2017, InVivo announced that the Company had halted a trial of its Neuro-Spinal Scaffold, a spinal cord injury treatment, after a third patient death. InVivo advised investors that the Company had decided to halt the trial while it discusses with the U.S. Food and Drug Administration whether to change the trial’s enrollment criteria.
On this news, InVivo’s share price has fallen as much as $0.80, or 32.65%, during intraday trading on July 31, 2017.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
SOURCE: Pomerantz LLP
ReleaseID: 470101
Source URL: http://marketersmedia.com/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-invivo-therapeutics-holding-corp-nviv/223692
Source: AccessWire
Release ID: 223692